Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
A Phase II trial for the everyday treatment against obesity and theovereating of unhealthy food, by nasal spray and a behavioural programme,will aim to prove that Lightlake's treatment can break the addictive habit ofunhealthy eating, significantly reduce weight, and train the mind to embarkon a healthier dietary lifestyle and sustained weight-loss.
Obesity is an epidemic that is resulting in millions of preventabledeaths worldwide. (1) The American Cancer Society estimates that over 100,000Americans are dying from obesity and over eating related cancers every yearand the estimated healthcare cost alone is $147 billion every year. (2)
By 2012, it's expected that more than two billion people will beoverweight and 600 million will be obese. The U.S. Center for Disease Controland Prevention and Department of Health in the UK both estimate that 60% ofmen and 50% of women and 25% of children will be obese by 2050 if currenttrends continue. (3)
Lightlake has been given ethical approval to begin subject selection forPhase II clinical trial under the direction of its trial coordinatorProfessor Hannu Eero Rafael Alho, Professor of Addiction Medicine, Universityof Helsinki. The Trial is being conducted in conjunction with the NationalInstitute for Health and Welfare, in Helsinki. It will last 6 months andresults are expected in the fall of 2010.
Lightlake is pioneering the treatment of one of the world's biggestkillers and will be initially focused on addressing one form of obesity -Binge Eating Disorder (BED) - that effects one in three obese people. To dateexisting interventions from diets to drugs and surgery have failed to delivera sustainable solution to the obesity epidemic that is resulting in theglobal healthcare crisis. Those products currently on the market havequestions of efficacy and may come with undesirable side effects. This trialmarks a new departure in the treatment of obesity.
Lightlake Therapeutics is an international team of research scientists,pharmacologists and doctors backed by investors, who are pioneering thesearch for a safe, effective and simple treatment for the epidemic of obesityand unhealthy eating. Its expertise is derived from an existing treatmentthat has recorded a 78% success rate in treating the over consumption ofalcohol.
Dr. David Sinclair, Ph.D., Lightlake's Chief Science Officer says:
"Most human behaviour is driven by a system of reinforcement controlledby powerful brain chemicals. We have learnt how to regulate these brainchemicals using an active compound that is extremely safe and effective, sothat bad eating habits are progressively reduced, and good eating ispromoted. Delivery is through a pocket sized nasal spray that is easy andconvenient to carry. The treatment begins working progressively from thefirst day to reduce the urge to eat unhealthily. One of the real marvels ofthe treatment is that it changes what you think about. Dieting and most otherweight reduction procedures have the opposite effect. They make you thinkmore and more about problem foods. Our method makes the person no longerconsider consuming the specific foods that are unhealthy."
The active compound used is patented to Lightlake Therapeutics for thetreatment of eating disorders and obesity.
Says Dr. Roy Eskapa, author of The Cure for Alcoholism:
"Everyone is looking for the holy grail of a safe and effective treatmentof obesity with minimal side effects. Many who have attempted the journeyhave fallen along the way. It's interesting to see that Lightlake'sintervention is based on a successful treatment for alcoholism. It's a largeleap from alcohol to obesity but Dr David Sinclair's experience and provensuccess brings believability and credibility to the possibility. "
This press release contains forward-looking statements. These statementsrelate to future events or our future financial performance and involve knownand unknown risks, uncertainties and other factors that may cause our or ourindustry's actual results, levels of activity, performance or achievements tobe materially different from any future results, levels of activity,performance or achievements expressed, implied or inferred by theseforward-looking statements. In some cases, you can identify forward-lookingstatements by terminology such as "may," "will," "should," "could," "would,""expects," "plans," "intends," "anticipates," "believes," estimates,""predicts," "projects," "potential" or "continue" or the negative of suchterms and other comparable terminology. These statements are only predictionsbased on our current expectations and projections about future events. Youshould not place undue reliance on these statements. Actual events or resultsmay differ materially. In evaluating these statements, you shouldspecifically consider various factors. These and other factors may cause ouractual results to differ materially from any forward-looking statement. Weundertake no obligation to update any of the forward-looking statements afterthe date of this presentation to conform those statements to reflect theoccurrence of unanticipated events, except as required by applicable law.
Notes to Editors
Dr. David Sinclair, Ph.D. - Chief Science Officer, Lightlake TherapeuticsInc
Dr. Sinclair began in alcoholism research at University of Cincinnati,discovering that the usual treatment, forced abstinence, actually increasescraving. After getting his doctorate, he joined the unit on prevention andtreatment of addictions for Finland's National Institute for Health andWelfare. He subsequently worked on the preclinical studies and clinicaltrials proving the concept and on practical implementations. His work isfeatured in Dr. Roy Eskapa's 2008 book, The Cure for Alcoholism. Based on hiswork, Dr. Sinclair published a behavioural programme for those with impulsedisorders known as the Sinclair Method that has proved highly effective in awide range of applications. He has patented similar treatments for variousforms of drug addiction including the use of naltrexone for treatingamphetamine abuse, and has been studying the use of naltrexone forpathological gambling and a new treatment for panic disorders.
(Due to the length of this URLs, it may be necessary to copy and pastethe hyperlink into your Internet browser's URL address field. Remove thespace if one exists.)1. http://www.medicalnewstoday.com/articles/158948.php 2. http://www.cdc.gov/obesity/data/trends 3. http://www.bharatbook.com/Market http://www.bharatbook.com/Market-Research-Reports/Booming-Global -Obesity-Drug-Market.html
SOURCE Lightlake Therapeutics Inc
You May Also Like